CD8A and neoplasm: We observed a significant increase in T cells (CD3+ (p = 0.002; adj p = 0.008) and CD8+ (p = 0.009; adj p = 0.018) in the total tumor microenvironment upon treatment with cryo-tremelimumab combination therapy compared with tremelimumab monotherapy (Fig. 5a).